Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.
With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.
Company Details
- Employees
- 30
- Address
- 15 Necco St, Lilly Gateway Labs
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://superluminalrx.com/
- HQ
- Boston, Massachusetts
Superluminal Medicines Inc. Questions
Superluminal Medicines Inc.'s website is https://superluminalrx.com/
Superluminal Medicines Inc.'s LinkedIn profile is https://www.linkedin.com/company/superluminalrx
Superluminal Medicines Inc. has
30 employees.
View email and phone details for 30
employees at Superluminal Medicines Inc..
Superluminal Medicines Inc.'s industry is
Biotechnology Research
Superluminal Medicines Inc.'s top competitors are
Mbx Biosciences, Inc.,
Bicara Therapeutics,
Zenas Biopharma,
Candid Therapeutics,
Oruka Therapeutics,
Spectrawave, Inc.,
Radiant Biotherapeutics,
Onl Therapeutics,
Pantera,
Xencor.
Superluminal Medicines Inc.'s categories are Biotechnology Research
